Envafolimab plus Lenvatinib for kidney cancer spread to the liver
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two medications (Envafolimab and Lenvatinib) for people with a type of kidney cancer called clear cell renal cell carcinoma that has spread to the liver. The goal is to see if this combination can shrink or control the liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of clear cell kidney cancer that has spread to the liver.
- You cannot have received any previous treatment for advanced kidney cancer.
- You must have at least one liver tumor that can be measured on a CT scan.
- You must be between 18 and 75 years old.
- Your overall health status must be good (able to carry out daily activities without help).
- Your liver, kidneys, and blood counts must meet certain lab test minimums.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy (Envafolimab) with a targeted therapy pill (Axitinib) as the first treatment for advanced kidney cancer. The goal is to see if this combination works better than standard treatments.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests combining the immunotherapy drug pembrolizumab with the targeted therapy lenvatinib for people with advanced clear cell kidney cancer that returned after completing pembrolizumab as an early treatment after surgery. It aims to see if this combination can shrink or control the cancer.
This trial tests a new combination of drugs (envafolimab, suvemcitug, and HAIC) to shrink advanced or unresectable liver cancer. It is for people who have not had systemic treatment before and have good organ function.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Hear when a new Clear Cell Renal Cell Cancer (ccRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.